teriparatide Report issue

Biologics Peptide Orphan Drug FDA Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Teriparatide was manufactured under the brand name FORTEO. FORTEO contains recombinant human parathyroid hormone (1-34), [rhPTH(1-34)], which has an identical sequence to the 34 N-terminal amino acids (the biologically active region) of the 84-amino acid human parathyroid hormone, that regulates calcium and phosphate in the body. FORTEO is indicated for the treatment of postmenopausal women with severe osteoporosis who are at high risk of fracture or who have failed or are intolerant to previous osteoporosis therapy. In addition, Forteo is used for the treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in men and women who are at increased risk for fracture. The biological actions of teriparatide is mediated through binding to specific high-affinity cell-surface receptors. Teriparatide is not expected to accumulate in bone or other tissues.   NCATS

Chemistry

  • SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc2cnc[nH]2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc3c[nH]c4ccccc34)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](Cc5cnc[nH]5)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](Cc6ccccc6)C(=O)O
  • InChIKey: OGBMKVWORPGQRR-UMXFMPSGSA-N
  • Mol. Mass: 4117.79
  • ALogP: Missing data
  • ChEMBL Molecules:
    teriparatide acetate  
    teriparatide  
More Chemistry

Pharmacology

Drug Pricing (per unit)

Australia

$274.4019

United States

$870.6050 - $3414.0200
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

ak159 | forsteo | forteo | hpth 1-34 | hpth 1-34 (acetate salt) | parathar | parathyroid hormone-related peptide (1-36) | pth (1-34) | pth-related protein (1-36) | pthrp (1-36) | rhpth (1-34) | teriparatide | teriparatide acetate | teriparatide recombinant human | zt-034

Organizations (112)

Research & Development (108)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (6)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (51)

Approved Indications (2)


 

Osteoporosis

Osteoporosis, Postmenopausal (approved 2002)

Experimental Indications - Clinical Trial Phases 1-4 (51)


 

Alveolar Bone Loss (Phase 4)

Ankle Fractures (Phase 4)

Anorexia Nervosa (Phase 2)

Arthritis, Rheumatoid (Phase 4)

Back Pain (Phase 3)

Bone Diseases (Phase 4)

Bone Diseases, Endocrine (Phase 1)

Bone Diseases, Metabolic (Phase 3)

Bone Marrow Diseases (Phase 4)

Bone Regeneration (Phase 4)

Cartilage Diseases (Phase 2)

Chronic Kidney Disease-Mineral and Bone Disorder (Phase 4)

Colles' Fracture (Phase 2)

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 2 (Phase 4)

Dialysis (Phase 3)

DiGeorge Syndrome (Phase 3)

Education (Phase 4)

Femoral Neck Fractures (Phase 3)

Fracture Healing (Phase 4)

Fractures, Bone (Phase 4)

Fractures, Stress (Phase 4)

Healthy Volunteers (Phase 1)

Heart Diseases (Phase 4)

Hip Fractures (Phase 2)

Humeral Fractures (Phase 4)

Hyperparathyroidism (Phase 1)

Hyperparathyroidism, Secondary (Phase 3)

Hypocalcemia (Phase 3)

Hypoparathyroidism (Phase 3)

Intervertebral Disc Degeneration (Phase 2)

Menopause (Phase 2/Phase 3)

Neoplasms (Phase 1)

Osteoarthritis, Knee (Phase 2)

Osteogenesis Imperfecta (Phase 4)

Osteoporosis ()

Osteoporosis, Postmenopausal (Phase 4)

Osteoporotic Fractures (Phase 2)

Parathyroid Hormone (Phase 3)

Periodontitis (Phase 1)

Pharmacological and Toxicological Phenomena (Phase 1)

Prostheses and Implants (Phase 2)

Psoriasis (Phase 2)

Quality of Life (Phase 4)

Renal Insufficiency, Chronic (Phase 4)

Shoulder Fractures (Phase 2)

Spinal Cord Injuries (Phase 4)

Spinal Fractures (Phase 3)

Spinal Fusion (Phase 2)

Spinal Injuries (Phase 4)

Spinal Stenosis (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 148
  • # of Trial Organizations: 108

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue